Paclitaxel Poliglumex OPAXIO/Capecitabine Regimen Well Tolerated And Active In Metastatic Breast Cancer

At the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO), data were presented from a phase II investigator-sponsored trial paclitaxel poliglumex (OPAXIO(TM), CT-2103) in combination with capecitabine in first-line treatment of patients with metastatic breast cancer (MBC). The goals of the study were to explore the tolerability and objective anti-tumor response rate as well as the disease-free progression and survival times of the regimen. Although the study did not meet its pre-defined endpoint of 21 or more responses in the first 41 patients, 20 patients (42 percent) of the 48 evaluable patients demonstrated a confirmed tumor response, including two complete responses and 18 partial responses. The authors concluded th...